Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes.

Reverté, LaiaYeregui, ElenaOlona, MontserratGutiérrez-Valencia, AliciaBuzón, Maria JoséMartí, AnnaGómez-Bertomeu, FredericAuguet, TeresaLópez-Cortés, Luis FBurgos, JoaquinBenavent-Bofill, ClaraBoqué, CarmeGarcía-Pardo, GracianoRuiz-Mateos, EzequielMestre, Maria TeresaVidal, FrancescViladés, ConsueloPeraire, JoaquimRull, AnnaCOVIDOMICS Study Group2023-05-032023-05-032022http://hdl.handle.net/10668/21851enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Alpha-GlobulinsBiomarkersCOVID-19Cholesterol EstersGlutamic AcidHumansSeverity of Illness IndexTreatment OutcomeFetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes.research article35075803open access10.1002/ctm2.7042001-1326PMC8787095https://doi.org/10.1002/ctm2.704https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787095/pdf